ECSP088890A - Co-cristal de maleato de azd1152 - Google Patents

Co-cristal de maleato de azd1152

Info

Publication number
ECSP088890A
ECSP088890A EC2008008890A ECSP088890A ECSP088890A EC SP088890 A ECSP088890 A EC SP088890A EC 2008008890 A EC2008008890 A EC 2008008890A EC SP088890 A ECSP088890 A EC SP088890A EC SP088890 A ECSP088890 A EC SP088890A
Authority
EC
Ecuador
Prior art keywords
azd1152
crystal
amino
maleate
ethyl
Prior art date
Application number
EC2008008890A
Other languages
English (en)
Inventor
Richard Anthony Storey
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36637528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088890(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP088890A publication Critical patent/ECSP088890A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona con un nuevo co-cristal de 2-{etil[3-({4-[(5-{2-[(3-fluorofenil)amino]-2-oxoetil}-1H-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}etil dihidrógeno fosfato (AZD1152) el cual es un inhibidor de la aurora quinasa que es útil en el tratamiento de enfermedades hiperproliferativas tal como el cáncer.
EC2008008890A 2006-05-16 2008-11-14 Co-cristal de maleato de azd1152 ECSP088890A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0609621.8A GB0609621D0 (en) 2006-05-16 2006-05-16 Novel co-crystal

Publications (1)

Publication Number Publication Date
ECSP088890A true ECSP088890A (es) 2008-12-30

Family

ID=36637528

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008890A ECSP088890A (es) 2006-05-16 2008-11-14 Co-cristal de maleato de azd1152

Country Status (22)

Country Link
US (1) US7625910B2 (es)
EP (1) EP2027114A1 (es)
JP (1) JP2009537498A (es)
KR (1) KR20090009297A (es)
CN (1) CN101448823A (es)
AR (1) AR060963A1 (es)
AU (1) AU2007251304A1 (es)
BR (1) BRPI0712791A2 (es)
CA (1) CA2650519A1 (es)
CL (1) CL2007001388A1 (es)
EC (1) ECSP088890A (es)
GB (1) GB0609621D0 (es)
IL (1) IL194862A0 (es)
MX (1) MX2008014550A (es)
NO (1) NO20084580L (es)
RU (1) RU2008149242A (es)
SA (1) SA07280243B1 (es)
TW (1) TW200813026A (es)
UA (1) UA95108C2 (es)
UY (1) UY30351A1 (es)
WO (1) WO2007132227A1 (es)
ZA (1) ZA200809172B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82058C2 (uk) * 2001-12-24 2008-03-11 Астразенека Аб Заміщені похідні хіназоліну як інгібітори ауроракінази, спосіб їх одержання, фармацевтична композиція на їх основі
AU2004247626B8 (en) * 2003-05-15 2011-05-19 Arqule, Inc. Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
WO2006044869A1 (en) * 2004-10-19 2006-04-27 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
EP2361254A1 (en) * 2008-12-05 2011-08-31 ArQule, Inc. Raf inhibitors and their uses
ES2528485T3 (es) * 2009-09-11 2015-02-10 Amgen, Inc N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina para su uso en el tratamiento del cáncer resistente a agentes antimitóticos
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
HUE034490T2 (en) * 2013-09-16 2018-02-28 Astrazeneca Ab Therapeutic polymer nanoparticles and methods for their preparation and use
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
JP6980385B2 (ja) 2014-03-26 2021-12-15 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited Ｆｇｆｒ阻害剤とｉｇｆ１ｒ阻害剤の組合せ
MA55696A (fr) 2014-03-26 2022-02-23 Astex Therapeutics Ltd Combinaisons
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HRP20220012T1 (hr) 2015-09-23 2022-04-01 Janssen Pharmaceutica Nv Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka
BR112018005637B1 (pt) 2015-09-23 2023-11-28 Janssen Pharmaceutica Nv Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82058C2 (uk) * 2001-12-24 2008-03-11 Астразенека Аб Заміщені похідні хіназоліну як інгібітори ауроракінази, спосіб їх одержання, фармацевтична композиція на їх основі
US7528121B2 (en) * 2002-12-24 2009-05-05 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use

Also Published As

Publication number Publication date
CL2007001388A1 (es) 2008-01-18
RU2008149242A (ru) 2010-06-27
CN101448823A (zh) 2009-06-03
AR060963A1 (es) 2008-07-23
UY30351A1 (es) 2008-01-02
JP2009537498A (ja) 2009-10-29
US20080045481A1 (en) 2008-02-21
BRPI0712791A2 (pt) 2012-09-04
UA95108C2 (en) 2011-07-11
IL194862A0 (en) 2009-08-03
US7625910B2 (en) 2009-12-01
MX2008014550A (es) 2008-11-27
SA07280243B1 (ar) 2010-12-01
TW200813026A (en) 2008-03-16
EP2027114A1 (en) 2009-02-25
GB0609621D0 (en) 2006-06-21
AU2007251304A1 (en) 2007-11-22
CA2650519A1 (en) 2007-11-22
KR20090009297A (ko) 2009-01-22
NO20084580L (no) 2009-02-05
ZA200809172B (en) 2009-12-30
WO2007132227A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
ECSP088890A (es) Co-cristal de maleato de azd1152
MX356584B (es) Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
UA107796C2 (en) Tetracyclic compound
MA32594B1 (fr) Amidophenoxyindazoles utiles comme inhibiteurs du c-met
CR10343A (es) Aminotetrahidropiranos como inihibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes
BR112014009993A2 (pt) método para o tratamento de tumores do estroma gastrointestinal
JO2870B1 (en) Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
ECSP099078A (es) Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
MY152282A (en) Compositions and methods for use antibodies against sclerostin
CR10479A (es) Modulares bencimidazolicos de vr1
MX2012002633A (es) Aminotetrahidropiranos como inhibidores de la dipeptidil peptidasa iv para el tratamiento prevencion de la diabetes.
WO2011080568A3 (en) Novel pyrimidine compounds as mtor and p13k inhibitors
WO2008046509A8 (en) Ltbp2 as a biomarker, therapeutic and diagnostic target
GEP20146125B (en) Aminopyrimidines as syk inhibitors
EA201170832A1 (ru) Пуриновые соединения
EP2257161A4 (en) AHCY-HYDROLASE INHIBITOR FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
BR112013033836A2 (pt) terapia de combinação
ATE474574T1 (de) Imidazoazephinonverbindungen
WO2006108680A3 (en) Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against protozoa and helminthes
BRPI0603784A (pt) lubrificante pessoal vaporizável
MX2010001577A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
EA201101193A1 (ru) Применение аторвастатин лактолов в качестве лекарственных средств
DOP2006000256A (es) Compuestos de pirimidinil benzotiofeno
MX2010001570A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.